19.52

1.19% +0.23

Edgewise Therapeutics Inc (EWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Edgewise Therapeutics Inc stock is currently priced at $19.52, with a 24-hour trading volume of 540.79K. It has seen a +1.19% increased in the last 24 hours and a +5.51% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $19.12 pivot point. If it approaches the $19.72 resistance level, significant changes may occur.

Previous Close:

$19.29

Open:

$19.74

24h Volume:

540.79K

Market Cap:

$1.82B

Revenue:

Net Income/Loss:

$-100.16M

P/E Ratio:

-14.57

EPS:

-1.34

Net Cash Flow:

$-97.69M

1W Performance:

+20.72%

1M Performance:

+5.51%

6M Performance:

+189.61%

1Y Performance:

+111.03%

1D Range:

$19.44

$20.12

52W Range:

$5.12

$20.90

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Name

Edgewise Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

303 735 8373

Address

3415 Colorado Avenue, Boulder

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

EWTX's Discussions on Twitter

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell
Apr-13-22	Initiated	RBC Capital Mkts	Outperform
Jan-28-22	Initiated	Goldman	Neutral

Edgewise Therapeutics Inc Stock (EWTX) Latest News

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

Zacks Investment Research

Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?

Zacks Investment Research

Insiders Buying Edgewise Therapeutics And 2 Other Stocks

Benzinga

Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet

Zacks Investment Research

Edgewise (EWTX) Rallies 35% on Issue of New Common Stock

Zacks Investment Research

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Edgewise Therapeutics Inc Stock (EWTX) Financials Data

Edgewise Therapeutics Inc (EWTX) Net Income 2024

EWTX net income (TTM) was -$100.16 million for the quarter ending December 31, 2023, a -48.08% decrease year-over-year.

Edgewise Therapeutics Inc (EWTX) Cash Flow 2024

EWTX recorded a free cash flow (TTM) of -$97.69 million for the quarter ending December 31, 2023, a -67.91% decrease year-over-year.

Edgewise Therapeutics Inc (EWTX) Earnings per Share 2024

EWTX earnings per share (TTM) was -$1.58 for the quarter ending December 31, 2023, a -25.40% decline year-over-year.

Edgewise Therapeutics Inc Stock (EWTX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
KOCH KEVIN	President and CEO	May 02 '24	Sale	18.91	3,152	59,604	14,478
Carruthers R Michael	Chief Financial Officer	May 02 '24	Sale	18.91	2,157	40,789	35,230
MOORE JOHN R	General Counsel	May 02 '24	Sale	18.91	1,956	36,988	3,252
Derakhshan Behrad	Chief Business Officer	May 02 '24	Sale	18.91	1,718	32,487	13,422
Russell Alan J	Chief Scientific Officer	May 02 '24	Sale	18.91	1,576	29,802	7,238
Russell Alan J	Chief Scientific Officer	May 01 '24	Option Exercise	0.00	5,208	0	8,814
Donovan Joanne M.	CMO	May 01 '24	Option Exercise	0.00	10,417	0	23,579
KOCH KEVIN	President and CEO	May 01 '24	Option Exercise	0.00	10,417	0	17,630
Derakhshan Behrad	Chief Business Officer	May 01 '24	Option Exercise	0.00	5,208	0	15,140
Carruthers R Michael	Chief Financial Officer	May 01 '24	Option Exercise	0.00	5,208	0	37,387

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.